MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical technology company pioneering a new treatment for type 2 diabetes (T2D), today announced the closing of a $50 million extension of its Series C financing. Arboretum Ventures joined as a new lead investor, with existing investors participating as well. The proceeds from this financing will fund completion of the company's pivotal ReCET Clinical Study and support the company's regulatory path to FDA approval.

This extension builds on the $88 million Series C that Endogenex closed in June 2024, bringing total Series C financing to $138 million.

Endogenex is developing a minimally invasive, outpatient endoscopic procedure that uses non-thermal pulsed electric fields to treat inflamed tissue and support healthy cell regeneration in the duodenum, the first section of the small intestine. Growing evidence suggests that when the duodenum is inflamed, it disrupts the gut's ability to sense and communicate with the organs that regulate blood sugar, appetite, digestion, and metabolism. This gut dysfunction may worsen or even contribute to the cause of type 2 diabetes.

"This financing puts us in a strong position to complete our pivotal study and take the ReCET System through FDA approval," said Stacey Pugh, CEO of Endogenex. "Type 2 diabetes continues to take a heavy toll on patients, providers, and the healthcare system. Even with the best available therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, the disease often continues to progress. We believe that is because an important part of the disease has gone untreated: the gut. By restoring the duodenum to a healthier ...